In conclusion, these studies indicate that CD38 is crucial for cell-mediated immuno-modulatory functions and pro-tumoral interactions with components of the microenvironment, thus supporting the use of monoclonal antibodies for the treatment of hematological and non-hematological malignancies. This evidence concerns the gene CD38 and hematologic disorder.